Astrazeneca PLC (NYSE:AZN) hit a new 52-week high on Friday . The stock traded as high as $35.04 and last traded at $34.47, with a volume of 7,132,119 shares. The stock had previously closed at $34.30.

Several equities research analysts have weighed in on AZN shares. Citigroup Inc. reissued a “buy” rating on shares of Astrazeneca PLC in a report on Saturday, June 25th. Shore Capital reissued a “hold” rating on shares of Astrazeneca PLC in a report on Wednesday, July 20th. Argus started coverage on Astrazeneca PLC in a report on Tuesday, July 12th. They issued a “hold” rating for the company. Deutsche Bank AG reissued a “buy” rating on shares of Astrazeneca PLC in a report on Tuesday, June 7th. Finally, Cantor Fitzgerald restated a “buy” rating on shares of Astrazeneca PLC in a research note on Thursday, July 28th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. Astrazeneca PLC currently has a consensus rating of “Buy” and an average target price of $36.71.

The stock has a market cap of $86.73 billion and a PE ratio of 39.18. The stock has a 50 day moving average price of $30.53 and a 200 day moving average price of $29.66.

Astrazeneca PLC (NYSE:AZN) last announced its earnings results on Thursday, July 28th. The company reported $0.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.76 by $0.07. The firm earned $5.60 billion during the quarter, compared to analyst estimates of $5.56 billion. During the same period last year, the company earned $1.21 earnings per share. The firm’s revenue for the quarter was down 4.0% compared to the same quarter last year. On average, equities research analysts predict that Astrazeneca PLC will post $2.47 EPS for the current fiscal year.

The business also recently disclosed a dividend, which will be paid on Monday, September 12th. Shareholders of record on Friday, August 12th will be given a dividend of $0.44 per share. The ex-dividend date is Wednesday, August 10th.

A number of hedge funds recently bought and sold shares of AZN. Genesee Valley Trust Co. boosted its stake in Astrazeneca PLC by 5.4% in the fourth quarter. Genesee Valley Trust Co. now owns 31,627 shares of the company’s stock worth $1,074,000 after buying an additional 1,617 shares during the last quarter. Morgan Stanley boosted its stake in Astrazeneca PLC by 16.3% in the fourth quarter. Morgan Stanley now owns 1,572,388 shares of the company’s stock worth $53,382,000 after buying an additional 220,787 shares during the last quarter. Westfield Capital Management Co. LP boosted its stake in Astrazeneca PLC by 11.8% in the fourth quarter. Westfield Capital Management Co. LP now owns 213,350 shares of the company’s stock worth $7,243,000 after buying an additional 22,450 shares during the last quarter. US Bancorp DE boosted its stake in Astrazeneca PLC by 8.2% in the fourth quarter. US Bancorp DE now owns 126,767 shares of the company’s stock worth $4,304,000 after buying an additional 9,638 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Astrazeneca PLC by 7.6% in the fourth quarter. Wells Fargo & Company MN now owns 2,009,893 shares of the company’s stock worth $68,236,000 after buying an additional 141,767 shares during the last quarter.

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.